New Perspectives in Gastric Cancer: Helicobacter pylori-Uninfected Pure Signet Ring Cell Carcinoma

  • Takeshi Setoyama
  • Shin’ichi MiyamotoEmail author
  • Mitsuhiro Nikaido
  • Hiroshi Seno


Although gastric cancer incidence and mortality rates remain high in Japan, they have decreased in recent years. This decline is thought to be attributable to the reduction of Helicobacter pylori (HP) infection rate (approximately 50% of the population born in the 1940s vs. 10% in the 1980s). However, some studies on HP-uninfected gastric cancer have reported that the prevalence of this type of cancer accounted for 5% at most. HP-uninfected gastric cancers include lesions related to autoimmune gastritis, Epstein–Barr virus infection, genetic factors such as hereditary diffuse gastric cancer (HDGC), and sporadic/nonhereditary cancers. Among sporadic HP-uninfected gastric cancers, pure signet ring cell carcinomas are reported to be the most common. In this chapter, clinicopathological characteristics of this type of cancer are discussed, compared with a case of HDGC. And speculation about the carcinogenic mechanisms (mainly focusing on CDH1 gene alteration) based on the evidences obtained from previous excellent mouse models are also introduced here.


Helicobacter pylori-uninfected gastric cancer Signet ring cell carcinoma E-cadherin CDH1 gene alteration 


  1. 1.
    Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefGoogle Scholar
  2. 2.
    Polk DB, Peek RM Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010;10:403–14.CrossRefGoogle Scholar
  3. 3.
    Plummer M, Franceschi S, Vignat J, et al. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136:487–90.CrossRefGoogle Scholar
  4. 4.
    Lee YC, Chiang TH, Chou CK, Tu YK, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150:1113–24.CrossRefGoogle Scholar
  5. 5.
    Rokkas T, Rokka A, Portincasa P. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol. 2017;30:414–23.PubMedPubMedCentralGoogle Scholar
  6. 6.
    The Editorial Board of the Cancer Statistics in Japan. Cancer statistics in Japan 2016. 2017.Google Scholar
  7. 7.
    Tsuda M, Asaka M, Kato M, et al. Effect of Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017;22:e12415.CrossRefGoogle Scholar
  8. 8.
    Matsuo T, Ito M, Takata S, Tanaka S, et al. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415–9.CrossRefGoogle Scholar
  9. 9.
    Yamamoto Y, Fujisaki J, Omae M, et al. Helicobacter pylori-negative gastric cancer: characteristics and endoscopic findings. Dig Endosc. 2015;27:551–61.CrossRefGoogle Scholar
  10. 10.
    Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guideline for clinical management and directions for future research. J Med Genet. 2010;47:436–44.CrossRefGoogle Scholar
  11. 11.
    Cutsem EV, Sagaert X, Topal B, et al. Gastric Cancer. Lancet. 2016;388:2654–64.CrossRefGoogle Scholar
  12. 12.
    Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis: pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol. 2013;10:529–41.CrossRefGoogle Scholar
  13. 13.
    Park JY, Lam-Himlin D, Vemulapalli R. Review of autoimmune metaplastic atrophic gastritis. Gastrointest Endosc. 2013;77:284–92.CrossRefGoogle Scholar
  14. 14.
    Toh BH. Diagnosis and classification of autoimmune gastritis. Autoimmun Rev. 2014;13(4–5):459–62.CrossRefGoogle Scholar
  15. 15.
    The Cancer Genome Atlas Research Network, Bass A, Thorsson V, Shmulevich B, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRefGoogle Scholar
  16. 16.
    Van Beek J, Zur Hausen A, Kranenbarg EK, et al. EBV-positive gastric adenocarcinoma: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol. 2004;22:664–70.CrossRefGoogle Scholar
  17. 17.
    Oliveira C, Pinheiro H, Figueiredo J, et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015;16:e60–70.CrossRefGoogle Scholar
  18. 18.
    Hansford S, Kaurah P, Li-Chang H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutation and beyond. JAMA Oncol. 2015;1:23–32.CrossRefGoogle Scholar
  19. 19.
    Horiuchi Y, Fujisaki J, Yamamoto N, et al. Biological behavior of the intramucosal Helicobacter pylori-negative undifferentiated-type early gastric cancer: comparison with Helicobacter pylori-positive early gastric cancer. Gastric Cancer. 2016;19:160–5.CrossRefGoogle Scholar
  20. 20.
    Kiso M, Yoshihara M, Ito M, et al. Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test: a multicenter study. Gastric Cancer. 2017;20:764–71.CrossRefGoogle Scholar
  21. 21.
    Horiuchi Y, Fujisaki J, Ishizuka N, et al. Study of clinical factors involved in Helicobacter pylori-uninfected, undifferentiated-type early gastric cancer. Digestion. 2017;96:213–9.CrossRefGoogle Scholar
  22. 22.
    Ono S, Kato M, Suzuki M, et al. Frequency of Helicobacter pylori-negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. Digestion. 2012;86:59–65.CrossRefGoogle Scholar
  23. 23.
    Van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guideline with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52:316–74.Google Scholar
  24. 24.
    Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implication for patient screening. J Pathol. 2004;203:681–7.CrossRefGoogle Scholar
  25. 25.
    Machado JC, Oliveira C, Carvalho R, et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric cancer. Oncogene. 2001;20:1525–8.CrossRefGoogle Scholar
  26. 26.
    Corso G, Carvalho J, Marrelli D, et al. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol. 2013;31:868–75.CrossRefGoogle Scholar
  27. 27.
    Cho SY, Park JW, Liu Y, et al. Sporadic early-onset diffuse gastric cancers have a high frequency of somatic CDH1 alterations, but a low frequency of somatic RHOA mutations compared with late-onset cancers. Gastroenterology. 2017;153:536–49.CrossRefGoogle Scholar
  28. 28.
    Humar B, Blair V, Charlton A, et al. E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Cancer Res. 2009;69:2050–6.CrossRefGoogle Scholar
  29. 29.
    Mimata A, Fukamachi H, Eishi Y, et al. Loss of E-cadherin in mouse gastric epithelial cells induces signet ring-like cells, a possible precursor lesion of diffuse gastric cancer. Cancer Sci. 2011;102:942–50.CrossRefGoogle Scholar
  30. 30.
    Hayakawa Y, Ariyama H, Stancikova J, et al. Mist1 expressing gastric stem cells maintain the normal and neoplastic gastric epithelium and are supported by a perivascular stem cell niche. Cancer Cell. 2015;28:800–14.CrossRefGoogle Scholar
  31. 31.
    Ranzani GN, Luinetti O, Padovan LS, et al. p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. Cancer Epidemiol Biomark Prev. 1995;4:223–31.Google Scholar
  32. 32.
    Shimada S, Mimata A, Sekine M, et al. Synergistic tumor suppressor activity of E-cadherin and p53 in a conditional mouse model of metastatic diffuse-type gastric cancer. Gut. 2012;61:344–53.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Takeshi Setoyama
    • 1
  • Shin’ichi Miyamoto
    • 2
    Email author
  • Mitsuhiro Nikaido
    • 2
  • Hiroshi Seno
    • 2
  1. 1.Department of Gastroenterology and HepatologyOsaka Red Cross HospitalOsakaJapan
  2. 2.Department of Gastroenterology and HepatologyKyoto University Graduate School of MedicineKyotoJapan

Personalised recommendations